CA2367590A1 - Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales - Google Patents
Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales Download PDFInfo
- Publication number
- CA2367590A1 CA2367590A1 CA002367590A CA2367590A CA2367590A1 CA 2367590 A1 CA2367590 A1 CA 2367590A1 CA 002367590 A CA002367590 A CA 002367590A CA 2367590 A CA2367590 A CA 2367590A CA 2367590 A1 CA2367590 A1 CA 2367590A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell
- tumor
- dendritic
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 178
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 127
- 108091007433 antigens Proteins 0.000 title claims abstract description 72
- 239000000427 antigen Substances 0.000 title claims abstract description 71
- 102000036639 antigens Human genes 0.000 title claims abstract description 71
- 238000000338 in vitro Methods 0.000 title claims description 14
- 230000006698 induction Effects 0.000 title description 6
- 208000017815 Dendritic cell tumor Diseases 0.000 title 1
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 126
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 78
- 238000000034 method Methods 0.000 claims abstract description 75
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 74
- 238000003501 co-culture Methods 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 22
- 238000009169 immunotherapy Methods 0.000 claims abstract description 18
- 238000009472 formulation Methods 0.000 claims abstract description 17
- 238000012258 culturing Methods 0.000 claims abstract description 9
- 238000010171 animal model Methods 0.000 claims abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 201000001441 melanoma Diseases 0.000 claims description 15
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 238000003306 harvesting Methods 0.000 claims description 6
- 210000001165 lymph node Anatomy 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 6
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 241000701806 Human papillomavirus Species 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 241000700584 Simplexvirus Species 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000003595 dermal dendritic cell Anatomy 0.000 claims description 5
- 210000003426 epidermal langerhans cell Anatomy 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 239000006285 cell suspension Substances 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 230000009257 reactivity Effects 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims description 3
- 239000002299 complementary DNA Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 238000012216 screening Methods 0.000 claims 1
- 238000004113 cell culture Methods 0.000 abstract description 4
- 238000012546 transfer Methods 0.000 abstract description 3
- 235000018259 Solanum vestissimum Nutrition 0.000 abstract 1
- 240000002825 Solanum vestissimum Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000004927 fusion Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 15
- 208000036142 Viral infection Diseases 0.000 description 13
- 230000009385 viral infection Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 230000000069 prophylactic effect Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000008188 pellet Substances 0.000 description 8
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 7
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- -1 ATCC T1B 146) Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Cette invention concerne des cellules T spécifiques à un antigène, lesquelles sont obtenues en cultivant des cellules T dans des formulations qui comprennent des combinaisons de cellules dendritiques et de cellules soit tumorales, soit infectées par un virus. Ces formulations comprennent de manière générale un hybridome d'au moins une cellule dendritique fusionnée à au moins une cellule qui est soit tumorale, soit infectée par un virus, ou des co-cultures de cellules dendritiques et de cellules soit tumorales, soit infectées par un virus. Les cellules T ainsi obtenues peuvent être utilisées dans des procédés d'immunothérapie par le transfert adoptif chez le patient de cellules T spécifiques à un antigène et autologues, ceci à l'aide de techniques bien établies. Ces cellules peuvent être utilisées comme agents permettant d'identifier des antigènes de tumeurs, et d'établir des modèles animaux.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28267999A | 1999-03-31 | 1999-03-31 | |
US09/282,679 | 1999-03-31 | ||
PCT/US2000/008472 WO2000057705A1 (fr) | 1999-03-31 | 2000-03-30 | Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2367590A1 true CA2367590A1 (fr) | 2000-10-05 |
Family
ID=23082644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002367590A Abandoned CA2367590A1 (fr) | 1999-03-31 | 2000-03-30 | Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1168924A4 (fr) |
JP (1) | JP2002539805A (fr) |
CN (1) | CN1353575A (fr) |
AU (1) | AU4183100A (fr) |
CA (1) | CA2367590A1 (fr) |
WO (1) | WO2000057705A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050169898A1 (en) | 1997-04-15 | 2005-08-04 | Jianlin Gong | Cell fusions and methods of making and using the same |
WO2001059073A2 (fr) * | 2000-02-11 | 2001-08-16 | Dana-Farber Cancer Institute, Inc. | Lymphocytes t cytotoxiques actives par des hybrides de cellules dendritiques |
DE69839215T2 (de) | 1997-04-15 | 2009-03-19 | Dana-Farber Cancer Institute, Inc., Boston | Dendritische zellhybride |
WO2001029193A2 (fr) * | 1999-10-22 | 2001-04-26 | Peter Leskovar | Constructions cellulaires adaptees a l'immunotherapie, leur production et leur utilisation |
DE10164819A1 (de) * | 2001-11-20 | 2005-05-19 | Deml, Ludwig, Dr. | Verfahren zur Identifizierung von Zielepitopen der T-Zell-vermittelten Immunantwort und zum Nachweis Epitop-spezifischer T-Zellen |
SI2511301T1 (en) | 2006-08-04 | 2018-05-31 | MedImmune Limited, | Human antibodies to ERBB 2 |
DE102010037622B4 (de) * | 2010-09-17 | 2012-07-12 | Lophius Biosciences Gmbh | Verfahren zum Nachweis, Differenzieren und Quantifizieren von T-Zellpopulationen mittels der Reverse Transkription quantitativen Real-Time PCR (RT-qPCR) Technologie |
EP2606897A1 (fr) | 2011-12-22 | 2013-06-26 | Laboratorios Del. Dr. Esteve, S.A. | Procédés et compositions pour le traitement des maladies causées par les virus enveloppés |
CN102827826B (zh) * | 2012-09-11 | 2017-07-04 | 赵永祥 | 一种诱导树突状细胞与肿瘤细胞融合的方法 |
WO2016145578A1 (fr) | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Procédés de traitement du cancer au moyen de lymphocytes t activés |
CN104830793A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
WO2016183037A1 (fr) | 2015-05-08 | 2016-11-17 | Wilson Wolf Manufacturing | Procédés de culture améliorés et dispositifs de test |
EP3316897A4 (fr) | 2015-07-02 | 2019-03-13 | Primevax Immuno-Oncology, Inc. | Compositions et procédés pour polythérapie utilisant le virus de la dengue et des cellules dendritiques |
CA2999881A1 (fr) | 2015-09-26 | 2017-03-30 | PrimeVax Immuno-Oncology, Inc. | Compositions et procedes pour produire des cellules dendritiques |
CN105532575A (zh) * | 2016-01-14 | 2016-05-04 | 中国科学院昆明动物研究所 | 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用 |
WO2018093907A1 (fr) | 2016-11-16 | 2018-05-24 | PrimeVax Immuno-Oncology, Inc. | Immunothérapies d'association pour le traitement du cancer |
WO2019183924A1 (fr) | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Procédés améliorés de thérapie cellulaire spécifique à l'antigène |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69634750T2 (de) * | 1995-03-31 | 2006-02-23 | Université Libre de Bruxelles | DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT |
DE69839215T2 (de) * | 1997-04-15 | 2009-03-19 | Dana-Farber Cancer Institute, Inc., Boston | Dendritische zellhybride |
JP2002500872A (ja) * | 1998-01-26 | 2002-01-15 | ジェンザイム・コーポレーション | 免疫エフェクター細胞ハイブリッド |
-
2000
- 2000-03-30 CA CA002367590A patent/CA2367590A1/fr not_active Abandoned
- 2000-03-30 JP JP2000607471A patent/JP2002539805A/ja active Pending
- 2000-03-30 AU AU41831/00A patent/AU4183100A/en not_active Abandoned
- 2000-03-30 WO PCT/US2000/008472 patent/WO2000057705A1/fr not_active Application Discontinuation
- 2000-03-30 CN CN00808298A patent/CN1353575A/zh active Pending
- 2000-03-30 EP EP00921528A patent/EP1168924A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU4183100A (en) | 2000-10-16 |
WO2000057705A1 (fr) | 2000-10-05 |
CN1353575A (zh) | 2002-06-12 |
JP2002539805A (ja) | 2002-11-26 |
EP1168924A4 (fr) | 2002-09-04 |
EP1168924A1 (fr) | 2002-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines | |
US7670611B2 (en) | Cancer immunotherapy with semi-allogeneic cells | |
AU2003302504B2 (en) | Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors | |
CA2367590A1 (fr) | Induction in vitro de cellules t specifiques a un antigene a l'aide d'immunogenes derives de cellules dendritiques-cellules tumorales ou de cellules dendritiques-cellules virales | |
US11026921B2 (en) | Compositions and methods of treating cancer | |
Kjaergaard et al. | Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine | |
US20110268767A1 (en) | Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses | |
US20100303868A1 (en) | Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
Tsang et al. | The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells | |
Cho et al. | In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses | |
US20050170503A1 (en) | In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens | |
Schreurs et al. | Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy | |
US20050042751A1 (en) | Generation and use of new types of dendritic cells | |
US20190125848A1 (en) | Dendritic cell-extracellular vesicle fusions and methods of using same | |
AU2016243626A1 (en) | Compositions and methods of treating multiple myeloma | |
Engleman | Dendritic cells: potential role in cancer therapy | |
Peshwa et al. | Generation of primary peptide-specific CD8+ cytotoxic T-lymphocytes in vitro using allogeneic dendritic cells | |
US20060153821A1 (en) | Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products | |
Rodeberg et al. | In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma | |
AU2017356295A1 (en) | Compositions and methods of treating cancer | |
Asada et al. | Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice | |
Ponsaerts | Dendritic cell vaccines for immunity and tolerance: mRNA electroporation as a tool for efficient gene transfer | |
AU2007202210A1 (en) | Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |